ISIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTSOF STOCKHOLDERS’ EQUITY
Years Ended December 31, 2014, 2013 and 2012
(In thousands)
Isis Pharmaceuticals, Inc. Stockholders’ Equity
Common stock
Additional
paid in
capital
equity
Accumulated
other
comprehensive
income (loss)
Accumulated
deficit
Total
stockholders’
Description
Shares Amount
Balance at December 31, 2011
. . . . . . . . . . 100,043 $100 $1,013,592 $ (770) $ (841,488) $ 171,434
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
— — — — (65,478) (65,478)
Change in unrealized gains (losses),
net of tax . . . . . . . . . . . . . . . . . . . . . . . . . .
— — — 13,250
— 13,250
Issuance of common stock in connection
with employee stock plans . . . . . . . . . . . .
1,438
2
9,468
—
— 9,470
2
⅝
percent convertible subordinated notes
redemption, equity portion . . . . . . . . . . . .
— — (12,041)
—
— (12,041)
2¾ percent convertible senior notes,
equity portion, net of issuance costs. . . . .
— — 57,560
—
— 57,560
Share-based compensation expense . . . . . . .
— — 8,571
—
— 8,571
Balance at December 31, 2012
. . . . . . . . . . 101,481 $102 $1,077,150 $12,480 $ (906,966) $ 182,766
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
— — — — (60,644) (60,644)
Change in unrealized gains (losses),
net of tax . . . . . . . . . . . . . . . . . . . . . . . . . .
— — — 8,600
— 8,600
Issuance of common stock in connection
with employee stock plans . . . . . . . . . . . .
5,372
5
62,953
—
— 62,958
Issuance of public common stock. . . . . . . . .
9,618
9 173,283
—
— 173,292
Share-based compensation expense . . . . . . .
— — 11,418
—
— 11,418
Balance at December 31, 2013
. . . . . . . . . . 116,471 $116 $1,324,804 $21,080 $ (967,610) $ 378,390
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
— — — — (38,984) (38,984)
Change in unrealized gains (losses),
net of tax . . . . . . . . . . . . . . . . . . . . . . . . . .
— — — 18,667
— 18,667
Issuance of common stock in connection
with employee stock plans . . . . . . . . . . . .
1,972
2
23,071
—
— 23,073
2¾ percent convertible senior notes
repurchase, equity portion. . . . . . . . . . . . .
— — (326,444)
—
— (326,444)
1 percent convertible senior notes,
equity portion, net of issuance costs. . . . .
— — 170,232
—
— 170,232
Share-based compensation expense . . . . . . .
— — 31,383
—
— 31,383
Excess tax benefits from share-based
compensation awards. . . . . . . . . . . . . . . . .
— — 1,463
—
— 1,463
Balance at December 31, 2014
. . . . . . . . . . 118,443 $118 $1,224,509 $39,747 $(1,006,594) $ 257,780
See accompanying notes.
F-6
